EUVIMEDEUVIMED entdecken
Klinische Studie (Phase II)Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial

Peter G M de Gooyer, Yara L Verschoor, Lauren D W van den Dungen, Sara Balduzzi, Hendrik A Marsman, Marnix H Geukes Foppen, Cecile Grootscholten, Simone Dokter, Anne G den Hartog, Wieke H M Verbeek, Karlijn Woensdregt, Joris J van den Broek und 8 weitere

Nature Medicine · 2024-11 · 30 (11) · 3284-3290

DOI: 10.1038/s41591-024-03250-w ↗

Kurz gefasst

Klinische Studie (Phase II) in der Zeitschrift Nature Medicine, online erschienen am 15.09.2024. Verfasst von Peter G M de Gooyer und 19 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Nivolumab, Colonic Neoplasms, Neoadjuvant Therapy, DNA Mismatch Repair. Die Arbeit wurde bisher 135-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Bristol-Myers Squibb.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Mismatch repair deficiency (dMMR) is found in approximately 15% of non-metastatic colon cancers (CCs) and is characterized by a defective DNA mismatch repair system, resulting in hypermutated and highly immunogenic tumors. Although patients with dMMR CC have limited benefit from chemotherapy, these tumors have been shown to respond exceptionally well to neoadjuvant anti-PD-1 plus anti-CTLA-4, with high rates of pathologic responses. Here, based on data from melanoma studies, we postulated a high efficacy and favorable toxicity profile of anti-PD-1 plus anti-LAG-3. In the NICHE-3 study, a total of 59 patients with locally advanced dMMR CC were treated with two 4-weekly cycles of nivolumab (480 mg) plus relatlimab (480 mg) before surgery. Pathologic response was observed in 57 of 59 (97%; 95% confidence interval (CI): 88-100%) patients, meeting the primary endpoint. Responses included 54 (92%; 95% CI: 81-97%) major pathologic responses (≤10% residual viable tumor) and 40 (68%; 95% CI: 54-79%) pathologic complete responses. With a median follow-up of 8 months (range, 2-19), one patient had recurrence of disease. The treatment displayed an acceptable safety profile, with all-grade and grade 3-4 immune-related adverse events (irAEs) occurring in 80% and 10% of patients, respectively. The most common irAEs were infusion-related reactions (29%), thyroid dysfunction (22%) and fatigue (20%). In conclusion, our results show that neoadjuvant nivolumab/relatlimab induces high rates of pathologic responses and that further investigation of this treatment in larger studies is warranted. These data add to the body of evidence in support of neoadjuvant immunotherapy regimens in dMMR CC. ClinicalTrials.gov identifier: NCT03026140 .

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NivolumabColonic NeoplasmsNeoadjuvant TherapyDNA Mismatch RepairHumansFemaleMiddle AgedMaleAgedAdultAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsAged, 80 and overLymphocyte Activation Gene 3 Protein

Substanzen

NivolumabAntibodies, Monoclonal, HumanizedLymphocyte Activation Gene 3 Protein

Autor:innen und Institutionen

  • Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Biometrics, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Surgery, OLVG, Amsterdam, The Netherlands.
  • Department of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Surgical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Surgery, St Jansdal Hospital, Harderwijk, The Netherlands.

Förderung

  • Bristol-Myers Squibb

Zitieren

APA

de Gooyer, P. G. M., Verschoor, Y. L., van den Dungen, L. D. W., Balduzzi, S., Marsman, H. A., Geukes Foppen, M. H., Grootscholten, C., Dokter, S., den Hartog, A. G., Verbeek, W. H. M., Woensdregt, K., van den Broek, J. J., Oosterling, S. J., Schumacher, T. N., Kuhlmann, K. F. D., Beets-Tan, R. G. H., Haanen, J. B. A. G., van Leerdam, M. E., van den Berg, J. G., & Chalabi, M. (2024). Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nature Medicine, 30(11), 3284-3290. https://doi.org/10.1038/s41591-024-03250-w

Vancouver

de Gooyer PGM, Verschoor YL, van den Dungen LDW, Balduzzi S, Marsman HA, Geukes Foppen MH, et al. Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial. Nature Medicine. 2024;30(11):3284-3290. doi:10.1038/s41591-024-03250-w

BibTeX
@article{deGooyer2024,
  author = {de Gooyer, Peter G M and Verschoor, Yara L and van den Dungen, Lauren D W and Balduzzi, Sara and Marsman, Hendrik A and Geukes Foppen, Marnix H and Grootscholten, Cecile and Dokter, Simone and den Hartog, Anne G and Verbeek, Wieke H M and Woensdregt, Karlijn and van den Broek, Joris J and Oosterling, Steven J and Schumacher, Ton N and Kuhlmann, Koert F D and Beets-Tan, Regina G H and Haanen, John B A G and van Leerdam, Monique E and van den Berg, Jose G and Chalabi, Myriam},
  title = {Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial},
  journal = {Nature Medicine},
  year = {2024},
  volume = {30},
  number = {11},
  pages = {3284--3290},
  doi = {10.1038/s41591-024-03250-w}
}
Kostenlos starten →